NEW YORK- In a report published in Nature Immunology, officials from Mount Sinai School of Medicine in New York state a soluble dimeric peptide-major histocompatibility complex chimera called DEF prevents the onset of type 1 diabetes in mice.
The mice, prone to the disease, were treated with DEF every 5 days. Ten of the 12 mice in the experiment resisted development of the disease for 4.5 months during the testing. Once the DEF injections halted, however, the mice developed diabetes within 15 days.
DEF is constructed on an immunoglobulin scaffold to bind to cognate T cells.
Information from Given Imaging
Low Vaccination Concerns Highlight Need for Fall and Winter 2023 Vaccination Campaigns
September 28th 2023Cases of COVID-19, RSV, and influenza are expected to rise this fall and winter season; yet, the number of people who plan on getting the vaccines for each of the infections remains low, according to the NFID announcement today.
Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants
September 27th 2023As COVID-19 restrictions eased up, other respiratory viruses began circulating alongside SARS-CoV-2. It's crucial to identify cases and understand the symptoms of these infections to track the evolution of the virus and what health care workers should look out for.
Poll: What Minimum Educational Requirement Should Infection Preventionists Have?
September 25th 2023Many infection preventionists (IPs) disagree on the minimum requirement to have the IP position. Let Infection Control Today know your opinion. Answer this poll, and send your thoughts to Senior Editor Tori Whitacre Martonicz at tmartonicz@mjhlifesciences.com.
How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2
September 25th 2023The interaction between the respiratory viruses SARS-CoV-2, influenza, and RSV, poses ongoing challenges. Personal protective measures, testing, and vaccination are critical components of our strategy to mitigate the impact of these viruses.
2 Clarke Drive
Cranbury, NJ 08512